Highly Active Antiretroviral Therapy Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A home-based rehabilitation intervention for people living with HIV and disability in a resource-poor community, KwaZulu-Natal: study protocol for a randomised controlled trial
Discussion The researchers aim to employ a novel task shifting approach to implement a needs-based home-based rehabilitation programme for people living with HIV in order to improve their quality of life and functional ability. It is hoped that this study will provide rehabilitation professionals and researchers with evidence that can be utilised to improve existing rehabilitation interventions for people living with HIV. Trial registration South African National Clinical Trials Register: NHREC#4094 (Date of registra...
Source: Trials - November 2, 2015 Category: Research Source Type: clinical trials

A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)
Condition: HIV-1 InfectionInterventions: Drug: dolutegravir (Tivicay®) - Phase 1; Drug: lamivudine (Epivir®) - Phase 2; Drug: dolutegravir (Tivicay®) - Phase 2Sponsors: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); ViiV HealthcareNot yet recruiting - verified August 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 6, 2015 Category: Research Source Type: clinical trials

A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)
Condition: HIV-1 InfectionInterventions: Drug: dolutegravir (Tivicay®) - Phase 1; Drug: lamivudine (Epivir®); Drug: dolutegravir (Tivicay®) - Phase 2Sponsors: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); ViiV HealthcareNot yet recruiting - verified August 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 6, 2015 Category: Research Source Type: clinical trials

Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed HAART
Conditions: Acquired Immunodeficiency Syndrome; Human Immunodeficiency Virus TypeIntervention: Sponsor: Triple O Research Institute PARecruiting - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 25, 2014 Category: Research Source Type: clinical trials